

**Physician Clinical Quality Indicators**

Indicator Title	Clinical Intent	Category	Strength of Recommendation	Source	Recommendation	Phase I	Phase II
Appropriate testing for children with pharyngitis	To ensure that members diagnosed with pharyngitis receive appropriate testing for streptococcus within a clinically appropriate timeframe.	Diagnosis	B	HEDIS	B	✓	
USE OF SPIROMETRY TESTING IN THE ASSESSMENT AND DIAGNOSIS OF COPD*	To ensure that all members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) receive an appropriate spirometry test to confirm the diagnosis within a clinically appropriate timeframe.	Diagnosis	B	HEDIS	B	✓	
Use of Narrow Spectrum Antibiotics for Patients with Acute Streptococcal Pharyngitis	To ensure that all eligible members with a diagnosis of acute streptococcal pharyngitis are treated with appropriate spectrum antibiotics.	Disease Management	B	Adapted from HEDIS.	B	✓	
Use of Long-Term Control Drugs for Persistent Asthma	To ensure that members with persistent asthma receive medication appropriate for long term control of asthma.	Disease Management	A (inhaled corticosteroid or inhaled corticosteroid combos) B (other cases of medication (i.e., most cell stabilizers, leukotriene modifiers, methylxanthines))	HEDIS	A	✓	
Beta Blocker Persistence Following a Heart Attack	To ensure that members who have been discharged alive from an acute inpatient setting with an AMI receive an adequate supply beta blocker medications over a predefined time period.	Disease Management	A (Treatment for MI) C (Physician Impact on Adherence)	HEDIS	A	✓	
Diabetic Retinal Exam*	To ensure that all diabetic members ages 18-75 receive at least 1 retinal or dilated eye exam during the measurement year.	Disease Management	B	HEDIS	B	✓	
CHILDHOOD IMMUNIZATION: MEASLES, MUMPS, AND RUBELLA (MMR)*	To ensure that all children 24 months and younger receive their MMR vaccination at the clinically appropriate timeframe.	Prevention	A	HEDIS	A	✓	
CHILDHOOD IMMUNIZATION: VARICELLA-ZOSTER VIRUS (VZV)*	To ensure that all eligible children 24 months and younger receive their VZV vaccination at the clinically appropriate timeframe.	Prevention	A	HEDIS	A	✓	
Glycosylated Hemoglobin (HbA1c) test for Diabetics*	To ensure that all diabetic members ages 18-75 receive at least 1 glycosylated hemoglobin test during the measurement	Prevention	B	HEDIS	B	✓	
Treatment of Cardiovascular conditions: monitoring lipid levels*	To ensure that members with cardiovascular conditions receive lipid level monitoring at a clinically appropriate frequency.	2 <sup>nd</sup> prevention	A	HEDIS	A	✓	
Colorectal Cancer Screening*	To ensure that members 50-80 years of age received appropriate screening for colorectal cancer.	Primary Prevention	A	HEDIS	A	✓	
MAMMOGRAPHY SCREENING*	To ensure that all eligible women age 40-69 receive a mammography screening test during the measurement year or year prior.	Screening	A (50 to 69) B (40 to 49)	HEDIS	A (50 to 69)	✓	
CERVICAL CANCER SCREENING*	To ensure that all women ages 21-24 receive a cervical cancer screening test during the measurement year or the 2 years prior.	Screening	A	HEDIS	A	✓	

LDL monitoring for diabetes*	To ensure that all members with diabetes receive LDL monitoring at a clinically appropriate frequency.	Screening	B (for most adults with diabetes) C (for adults with low-risk lipid values [LDL < 100 mg/dl, HDL > 50 mg/dl, and triglycerides <150 mg/dl])	HEDIS	B	✓	
Medical attention for diabetic nephropathy*	To ensure diabetic members ages 18-75 receive a diabetic nephropathy screening test during the measurement year.	Screening	B	HEDIS	B	✓	
Osteoporosis screening following fracture*	To ensure that women age 51 or older who experience a fracture receive a bone mineral density (BMD) test or pharmacotherapy for osteoporosis during the 6 months after the fracture.	Screening	A	HEDIS	B	✓	
Inappropriate Use of Antibiotics for Upper Respiratory Infections (URI)	To ensure that children diagnosed with nonspecific upper respiratory infections are not being inappropriately treated with antibiotics.	Disease Management	B	Adapted from HEDIS.	B		✓
Appropriate Use of Antibiotics for Patients with Acute Otitis Media for Children 2 Months - 12 Years	To ensure that all eligible members with a diagnosis of acute otitis media receive the appropriate first line antibiotic treatment.	Disease Management	B	HBI	B		✓
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis	To ensure that all members with rheumatoid arthritis have had at least one ambulatory prescription dispensed for a disease modifying anti-rheumatic drug (DMARD).	Disease Management	A	HEDIS	A		✓
Inappropriate Antibiotic Treatment for Adults with Acute Bronchitis	To ensure that members without comorbidity diagnosed with bronchitis are not being inappropriately treated with antibiotics.	Utilization	A	HEDIS	A		✓
Pneumococcal Vaccine for the Elderly and Other High Risk Groups	To ensure that all the elderly and other high risk members receive a pneumococcal vaccination.	Prevention	A	HBI	B		✓
Follow-up after Initial Diagnosis and Treatment of Colorectal Cancer: Colonoscopy	To ensure that all eligible members who have been newly diagnosed with colorectal cancer receive follow up colonoscopy within 15 months after resection.	Disease Management	A	HBI	B		✓
Annual Visual Field Tests for Patients with Primary Open Angle Glaucoma	To ensure that all members diagnosed with primary open angle glaucoma receive an annual visual field test.	Disease Management	A	HBI	B		✓
Radiation Therapy Following Breast Conserving Surgery	To ensure that all eligible women who underwent breast conserving surgery receive follow up radiation therapy within a clinically appropriate timeframe.	Disease Management	A	HBI	A		✓
Lipid Level monitoring for patients receiving ISOTRETINOIN (ACCUTANE)	To ensure that all members who were initiated on oral isotretinoin (Accutane) receive pretreatment and follow-up lipid monitoring tests.	Disease Management	A	HEDIS	B		✓
Statin Treatment for Members with Diabetes	To ensure that all members with diabetes ages 40 years and older filled at least 1 prescription for a statin (HMG-CoA reductase inhibitor) during the measurement year.	Prevention	A	HBI	A (type II diabetes milletus) B (type I diabetes milletus)		✓
Childhood Immunizations: DTaP/DT	To ensure that all eligible children receive their diphtheria, tetanus, and pertussis vaccination within a clinically appropriate timeframe.	Prevention	A	HEDIS	A		✓

ACE inhibitor use in congestive Heart Failure	To ensure that all eligible members identified as having congestive heart failure receive an ACE inhibitor or ARB therapy within a clinically appropriate timeframe.	Disease Management	A	HBI (Adapted from ACC/AMA / NQF guidelines )	A (Class C Heart Failure [Symptomatic HF] with reduced LVEF) B (Class A Heart Failure [At risk of HF]) B (Class B Heart Failure [Structural abnormality but no symptoms]) C (Class C Heart Failure [Symptomatic HF] with normal LVEF) C (Class D Heart Failure [End-stage refractory HF])		✓
Treatment of Community Acquired Pneumonia: General	To ensure that all members diagnosed with community acquired pneumonia received first line antibiotics in the outpatient setting.	Disease Management	A	HBI	B		✓
Chronic Kidney Disease: Monitoring Calcium	To ensure that members with chronic kidney disease, but who are not on dialysis are monitored for blood calcium levels at least annually.	Disease Management	A	National Kidney Foundation Kidney Disease Outcome Quality Initiative Guideline /Adapted by HBI	B		✓
Chronic Kidney Disease: Monitoring Parathyroid Hormone (PTH)	To ensure that members with chronic kidney disease, who are not undergoing dialysis, are monitored for PTH levels at least once annually.	Disease Management	A	National Kidney Foundation Kidney Disease Outcome Quality Initiative Guideline /Adapted by HBI	B		✓
Chronic Kidney Disease: Monitoring Phosphorus	To ensure that members with chronic kidney disease but who are not on dialysis are monitored for blood phosphorus levels at least once annually.	Disease Management	A	National Kidney Foundation Kidney Disease Outcome Quality Initiative Guideline /Adapted by HBI	B		✓
Osteoporosis screening for Patients on Systemic Corticosteroids	To ensure that members who filled prescriptions for 180 day supply of systemic corticosteroids receive osteoporosis screening or treatment.	Medication Monitoring	A	HBI	B		✓
Risk Adjusts Obstetric Complications: Perineal Trauma after Vaginal Delivery			A				✓

Follow-up for Diabetic Retinopathy	To ensure that members diagnosed with diabetic retinopathy receive follow up visits with an eye care professional at least annually.	Disease Management	A	HBI	B	✓
Use of Diuretics as First Line Therapy for New Starts on Antihypertensive Pharmacotherapy	To ensure that eligible members receiving anti-hypertensive pharmacotherapy are initially treated with a thiazide diuretic	Disease Management	A	HBI	A	✓
Appropriate Monitoring for Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers Use, and/or Diuretics	To ensure that all members who received diuretics, angiotensin converting enzyme (ACE) inhibitors, and/or angiotensin receptor blockers (ARB) receive appropriate laboratory monitoring at least annually.	Medication Monitoring	A	HEDIS	B	✓
Appropriate work up Prior to Endometrial Ablation Procedure	To ensure that all women have endometrial sampling performed before undergoing an endometrial ablation.	Disease Management	A	HBI	B	✓
Appropriate use of Antibiotics for Patients with Acute Sinusitis	To ensure that all eligible members with a diagnosis of acute sinusitis receive the appropriate first line antibiotic treatment.	Disease Management	A	HBI	B	✓
Inhaled corticosteroids as First Line Treatment of Asthma	To ensure that all members identified as taking adjunctive treatments for asthma (i.e., methylxanthines, cromolyn sodium, nedocromil, leukotriene modifiers, long acting beta-2 agonist) are also on an inhaled corticosteroid as a first line agent.	Disease Management	A	HBI	A	✓
Glaucoma Screening in Older Adults	To ensure that all members 67 years and older receive screening for glaucoma at least every 2 years	Screening	A	HEDIS	B	✓
Chronic Kidney Disease: Lipid Tests	To ensure that all eligible members identified as having chronic kidney disease (CKD) receive a lipid test at a clinically appropriate frequency.	Disease Management	A	HBI	B	✓
Pharmacologic Management of Migraine Headaches	To ensure that members with moderate to severe migraine without contraindications receive recommended first line therapy (i.e., triptans, dihydroergotamine [DHE], and ergotamine) prior to rescue medications such as butalbital-containing analgesics, or opiate analgesics.	Disease Management	A	HBI	B	✓
Pharmacological Treatment of Osteoporosis	To ensure that all members with osteoporosis or fragility fractures received appropriate pharmacologic therapy.	Disease Management	A	HBI/ AMA Consortium	B	✓
Prenatal Screening: Screening for HIV in Early Pregnancy	To ensure that all pregnant members are screened for HIV.	Prevention	A	HBI	A	✓
Follow-up examination after diagnosis and treatment of skin cancers	To ensure that all members who have been diagnosed with skin cancer receive the appropriate follow up at least annually.	Disease Management	A	HBI	B	✓
Hepatic Enzyme Monitoring for Statin Use After Initiating Therapy	To ensure that eligible members newly initiated on statin therapy receive baseline liver function tests.	Medication Monitoring	A	HBI	B	✓
Visual Field Test for Patients with Suspected Glaucoma	To ensure that eligible members diagnosed with suspected glaucoma receive a visual field test at the clinically appropriate frequency.	Screening	A	HBI	B	✓

\* Indicated Measures that have Physician Self reporting capabilities